Isodiol International, Inc, is a global CBD innovator specializing in the development of pharmaceutical and nutraceutical products.

SUMMARY OVERVIEW

2

INTR

OD

UC

TI O

NCONTENTS >>

3

4

6

7

8

9

International Growth

History Timeline

Key Highlights

Key Milestones

Bulk Products

BIOACTIVE™

10 Pharmaceutical

11 ISODERM™

12 Consumer Products

14 Key Members

15 Contact

3

POISED FOR INTERNATIONAL GROWTH AND PHARMACEUTICAL DRUG DEVELOPMENT

Early Stage With Huge Potential

Isodiol’s objective is to become the worldwide leader in the development and sales of CBD based pharmaceuticals and consumer wellness products. Its mission is to create a cultural movement by building awareness and social acceptance throughout the world.

Isodiol maintains exclusive and unrestricted access to large scale hemp production capacity and leverages its patented, natural, GMP extraction methods to avoid costly synthetic manufacturing processes. The extracted CBD can be delivered as raw material or formulated into oils, cosmetics, foods and pharmaceutical products. Globally, legislation is being passed to allow hemp cultivation, production and manufacturing for CBD products. Isodiol is working with local health authorities globally to develop and implement regulatory standards for product quality and has multiple clinical studies and trials being conducted.

4

‘09

In 2009, Isodiol began researching medical studies where synthetic cannabidiol (CBD) was successful in treating serious medical conditions like Epilepsy and Meige Syndrome. From 2009 -11, Isodiol worked to build a commercially feasible extraction process and supply chain of natural hemp derived CBD.

In 2011, the first manufacturing facility was setup to process pure, natural CBD and ISO99™ BIOACTIVE CBD™ was born.

‘11

‘12

‘13 2013-15: 2 years of clinical studies forCBD Skincare and the development of the CannaCeuticals skincare line.

HISTORY OF ISODIOL

1st Crystalline CBD Manufacturer1st With ISO9001 and GMP Certification On Production

1st Crystalline Derived From EU Certified Organic Hemp

Cebidiol™ is developed: A micro-encapsulation method for CBDwas developed for use in skincare and cosmetic products.

5

NanoUltra™ is developed: nanoemulsified, ISO99™ CBD suspended in water that can be used in beverage formulation

‘14

Heneplex™ is developed: full spectrum phytocanninoid nano-complex for consumer wellness products

Isodiol develops a pain cream featuring an OTC approved ingredient (Menthol)

‘15

‘16

Isodiol launches a white label program and begins expansion of its finished goods product line and new brand development.

‘17

Isodiol merges with Laguna Blends, becoming Isodiol International, Inc under the CSE Symbol: ISOL

1st to Use Nanotechnology and Microencapsulation

1st to Formulate CBD Into Bevera ges

1st OTC Compliant Topical and Clinical Study for Skincare P roducts

‘18

Isodiol, through its subsidiary BSPG Labs, is granted approval from MHRA for an API on its CBD for use in pharmaceutical applications.

6

KEY INVESTMENT

HIGHTLIGHTS CSE DATA AS OF 04/17/2018

SYMBOL: ISOL

(In Canadian Dollars)

Closing Price: $1.04

Market Cap: $364 Million

52 Week High: $2.14

52 Week Low: $0.125

50 Day Avg, Volume: 3.11 Million

Capital Structure

Issued and Outstanding Pre Acquisition May 2017 70,000,000

Acquisitions:

ISO International LLC May-2017 52,000,000

Pot-O-Coffee May-2017 25,000,000

CBD Naturals May-2017 4,000,000

Bradley's Bioscience Nov-2017 1,600,000

Financing Raised in Fiscal 2018

C3 Global Biosciences Inc Dec-2017 1,100,000

BeTru Organics Inc Dec-2017 1,500,000

$45,000,000 80,000,000

Total Issued and Outstanding 350,200,000

Insider and Directors 75,000,000

Compass Clinics April-2018 2,000,000

BSPG-UK | Purodiol Brazil April-2018 38,000,000

7

Since Being Acquired and Listed On the Canadian Securities Exchange (CSE), Key Milestones/Achievements Include:

• Distribution Channels in North America, Latin America, South America, Europe, including mainstream channels such as FARMA USA (Brazil), Threshold Enterprises, and United Natural Foods (UNFI).

• Signed Definitive Licensing Agreement with Canopy Growth Corporation (WEED:CA) for Company’s Pot-O-Coffee and Pot-O-Tea.

• Brazilian Health Regulatory Agency (ANVISA) approval of ISODERM™ and ISODIOLEX™, enabling both to be prescribed by doctors and neurologists for the treatment of Epilepsy and Parkinson's Disease.

• Acquired 99% of Purodiol Do Brasil Ltda (PUR-Brazil). PUR-Brazil supplies Purodiol pharmaceutical products under ANVISA regulations and is currently involved in multiple clinical studies and trials.

• Announced product placement of Pot-O-Coffee and Pot-O-Tea in select Winn- Dixie stores throughout East Coast.

• Signed Licensing Agreement with Level Brands Inc, where the companies will work to develop and market consumer products for subsidiaries Kathy Ireland Health & Wellness and Ireland Men One (I'M1).

• Signed a Licensing Agreement with Livecare Health Canada Inc, granting Isodiol the exclusive right to use Livecare's Telehealth Platform relating to all cannabis, cannabis-derived, cannabinoid and phytoceutical products.

• Announced Partnership with Europe's leading MMA promoter, Cage Warriors, through its brand Iso-Sport™.

• Reported unaudited Q3 revenues for the period ended December 31, 2017 of _$5.89 million CDN a for net operational profit of $202,254 CDN – a 16% increase from Q2.

• Completed acquisition of Biosynthesis Pharma Group Limited (“BSPG”) in the UK. BSPG is actively involved in multiple clinical trials and studies globally and produces an MHRA approved Active Pharmaceutical Ingredient (API) CBD Molecule for use in pharmaceutical applications.

• Signed Letter of Intent to acquire 100% of leading specialty vape retailer KURE Corp, a company with unaudited fiscal 2018 revenue of 8.8 million USD.

• Signed Definitive Agreement to acquire premier bottling facility, Azure Bottling LLC, with full capacity running approximately 5.3 million bottles per month.

• Announced further international expansion in Latin America with Scythian Biosciences Corp for distribution in Argentina, Jamaica, and Columbia.

• Commenced development of a new state-of-the-art processing facility in Yunnan, China that will process over 15 metric ton of hemp biomass daily for the extraction of cannabinoids and terpenes for use in medical, nutraceutical, food and cosmetic industries.

• Signed Definitive Agreement to acquire a 19.9% equity stake in Compass Cannabis Clinic and obtained exclusive CBD distribution rights for its family of brands through the Compass distribution network.

8

Isodiol is a world leader in the sale of BIOACTIVE CBD™ and manufactures more than 30 finished products. The Company also maintains exclusive agreements to supply phytoceutical derivative solutions to product manufacturers and formulators.

BU

LK

PR

OD

UC

TS

This is where it all began. Our ISO99™ BIOACTIVE CBD™ was the original and is still the best hemp derivative of its kind.

As one of the largest sources for CBD worldwide, at Isodiol we’re proud tooffer the most Bioactive and purest quality product. We are committed to sustainable agriculture, sourcing our raw ingredients from NON-GMO crops grown without heavy metals, pesticides and herb icides.

SEED OIL

BIOMASSCRYSTALLIN

E

9

BIOACTIVE CRYSTALLINE BIOACTIVE OIL

A concentrate ofnanoemulsified CBD

suspended in water forformulations in beverages.

A proprietary formulationfeaturing microencapsulated

CBD for use in topicalapplications.

A synergistic blend of CBD and terpenes,

this formula is excellent for both food and

beverage additives.

BULK INGREDIENTS FOR FORMULATION

10

PH

AR

MAC

EU

TIC

AL

The Isodiol RAPID PATCH is a fast-actingtopical pain relief solution, powered by

lidocaine, menthol and ISO99™

While the lidocaine provides soothinganesthetic properties to calm nerves andstop pain impulses to the brain, Menthol

adds analgesic qualities, penetratingdeeply to help relieve pain in muscles

and tendons.

RAPID COOLING PAIN CREAM™ deliverscontinual soothing relief for muscles, joints,

arthritis, back and knee pain.

Formulated with Bioactive Cebidiol™ andcombined with stimulating menthol andeight homeopathic ingredients including

lavender, rosemary and other essential oils,this cooling gel is a fast acting topicalpain relief solution, ideal for use after

strenuous activity.

11

Isodiol has received approval from the Brazilian Health Regulatory Agency (ANVISA) for the approval of its pharmaceutical grade Cannabidiol (CBD) product, ISODERM™. This product isplaced on the Special Category List for alternative therapies which is able to be prescribed by

medical doctors and neurologists.

Additional submissions for regulatory approval: Mexico, Chile, Uruguay, Paraguay, Argentina, and other Latin American countries

ADVANCED BY PATENTED BONATH™ DELIVERY

(BACK OF THE NECK AT THE HAIRLINE)

ISODERM DIRECT EFFECTS TECHNOLOGY™ delivers ISO99™ directly to the critical area to modulate "Afferent Neural Input" to the brainstem and other CNS structures by application to the back of the neck at the hair line (BONATH™). With ISO99™, ISODERM™ offers the most effective and Bioactive form of CBD available in the marketplace.

DOCTOR DEVELOPED

Dr. Ron Aung-Din developed DIRECT EFFECTS TECHNOLOGY™ to help more people find natural relief that may be afforded by phytocannabinoid advancements.

As a neurologist with over 35 years of experience in General Neurology and Neuropsychiatry, Dr. Ron specializes in epilepsy, multiple sclerosis, Alzheimer’s Disease, dementia, migraine and tension headaches, and other disorders and diseases affecting the central nervous system.

• Applied to skin at the back of the neck at the hairline

• Uses an advanced patented technology called Direct Effects Technology™ to rapidly facilitate the delivery of active ingredients.

• Unique and gentle combination that works without the concerns of systemic side effects and drug interactions commonly encountered with systemic neuroactive compounds.

12

CO

NS

UM

ER

PR

OD

UC

TS

13

Iso-Sport™ produces a hemp-based product line to support the unique performance needs of professional and prosumer athletes.

Pot-O-Coffee produces premium blends of coffee, tea and hot cocoa infused with cannabis extracts in K-Cup™ and ready-to-drink (RTD) form.

CannCeuticals is a luxury skincare brand that specializes in luxury anti-aging formulas using micro-encapsulated BIOACTIVE CBD™

Isodiol produces pure BIOACTIVECBD™ derived from Hemp,for bulk sales and formulation,including its own line of rawingredient technologies andfinished products.

0.33 FL OZ (10mL)

BIOACTIVE HEMP OILTINCTURE

ISO1000

0.33 FL OZ (10mL)

BIOACTIVE HEMP OILTINCTURE

ISO1500

0.33 FL OZ (10mL)

BIOACTIVE HEMP OILTINCTURE

ISO2500

Dietary Supplement1 FL OZ (30mL)

GRAPE FLAVOR

CALM

May

Hel

p Pr

omot

e Ca

lmne

ss N

atur

ally

Dietary Supplement1 FL OZ (30mL)

BRAI

NM

ay H

elp

Mai

ntai

n N

euro

-Agi

lity

BERRY FLAVOR MELON FLAVOR

DIS

COM

FORT

May

Hel

p Ea

se T

empo

rary

Dis

com

fort

Dietary Supplement1 FL OZ (30mL) 1 kilo

Bulk Material For Formulation

100% Natural, Anhydrous Hemp Oil

NET WT. 250g

™

14

THE ISODIOL TEAM Key Members

Isodiol has a highly skilled team of Global leaders that are constantly innovating and creating standards for the Industry.

Marcos Agramont, Chief Executive Officer and Director

Mr. Agramont has been a leading innovator in the Cannabis Industry for the last five years developing products for domestic and international channels. He has pioneered delivery systems, regulations and processes for major brands in order to meet safety standards and compliance. He was instrumental in implementing innovative delivery apparatuses with concise servings, at a time when no accurate measuring of dosage for general usage existed. Mr. Agramont has helped introduce CBD to the pharmaceutical global markets including Japan, Latin America, the European Union and Australia.

Troy Nihart, Presiden t of ISO International, LLC

Troy has over 20 years of business development and entrepreneurship experience and has been an integral part of the CBD industry over the last 4 years. He has been instrumental in the development of an international supply chain for the US Market of hemp derived CBD and has developed some of the most recognized brands in the cannabis industry.

Aman Parmar - Chairman

His corporate experience includes twelve years working with both public and private companies in the Health Care, Resource, Manufacturing and Real Estate sectors. Aman has extensive experience in the capital markets and has been involved in corporate restructurings and financings for both public and private companies. He obtained a Chartered Accountant designation in 2012 and holds a Bachelor of Technology in Accounting from the British Columbia Institute of Technology.

Bryan Loree, CFO

Mr. Loree has approximately ten years of experience providing chief financial officer, accounting, financing, and management services to numerous issuers on the TSX Venture Exchange, Canadian Securities Exchange, and private companies. Mr. Loree is a CPA, CMA and possesses a BA from Simon Fraser University.

Dr. Ronald Aung-Din, Medical Advisor and Inventor of Direct Effects Technology

Dr Aung-Din, MD, practices General Neurology and Neuropsychiatry in Sarasota, FL. In 2009, Dr. Aung-Din founded AfGin Pharma, LLC, a research and development biopharmaceutical company dedicated to Direct Effects Topical Neuro-Affective Therapy. To date, 7 patents relating to the technology have been granted by USPTS and the EU and Australian patent offices.

15

CORPORATE DIRECTORY

Investor Contact

Mike Parmar

+1-604-409-4409

mikeparmar@isodiol.com

Stock Symbols:

CSE: ISOL

OTC: ISOLF

GERMANY: LB6A.F

@isodiol

24

CSE: ISOL | OTC: ISOLF | GERMANY: LB6A.F

www.isodiol.com | +1 855-979-6751